Issue 42 - The Cancer Letter

Vol.

No.

November 06, 2020Nov 06, 2020

Free

DOWNLOAD THE PDF

Steven Libutti: Trusting science as COVID's new wave looms over New Jersey

Cover Story

Conversation with The Cancer Letter COVID-19 & Cancer Free

Steven Libutti: Trusting science as COVID's new wave looms over New Jersey

By Paul Goldberg

As he watches COVID-19 numbers climb in New Jersey, Steven K. Libutti reviews all the things he had learned last spring, when the pandemic first slammed the state.

COVID-19 & Cancer Free News Analysis

Election results notwithstanding, Trump stands poised to deliver blows to NIH, FDA, public health, research

By Matthew Bin Han Ong

Free

A slice of carrot cake with cream cheese frosting will not make the turmoil go away, but it can't hurt

By Chase Sloan

Clinical Free Trials & Tribulations

Living with cannabis: The goal of helping cancer patients live in comfort deserves data now

By Dylan M. Zylla

In Brief

Timothy W. Mullett named chair of the Commission on Cancer of the American College of Surgeons

Donna D. Zhang receives $7.3 million NIEHS grant to research arsenic-induced lung cancer, Type 2 diabetes

Clinical Roundup

Cancer patients, clinicians find value in electronic real-time symptom reporting

Colon cancer surgery performed by highly skilled surgeons improves long-term survival for patients

Active surveillance is safe for African Americans with low-risk prostate cancer

Nerves keep pancreatic cancer cells from starving, study finds

Large-scale cancer proteomics study profiles protein changes in response to drug treatments

Drugs & Targets

Lynparza approved in the EU as first-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer

Kymriah receives approval for commercial manufacturing in Japan

Merck to acquire VelosBio for $2.75 billion

NCI Trials

NCI Trials for Nov. 2020

The National Cancer Institute approved the following clinical research studies last month.

PREVIOUS ISSUE

NEXT ISSUE